Neurocrine Biosciences Inc (NBIX NASDAQ) stock market data APIs
$142.3654
-0.85(-0.6%)
as of December 18, 2025
Try our APIs with
free plan!
Neurocrine Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Prev. Close
142.3654
Open
141.5189
High
144.9091
Low
141.2763
52 wk Range
84.23-160.18
Market Cap
14 142 M
P/E Ratio
33.933
Shares Outstanding
99 706 K
Revenue
2 683 M
EPS
2.17
Beta
0.274
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Neurocrine Biosciences Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Neurocrine Biosciences Inc data using free add-ons & libraries
Get Neurocrine Biosciences Inc Fundamental Data
Neurocrine Biosciences Inc Fundamental data includes:
- Net Revenue: 2 683 M
- EBITDA: 570 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: 2.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Neurocrine Biosciences Inc News
New
Exploring Three High Growth Tech Stocks In The US Market
Amidst a backdrop of declining major stock indexes, with the S&P 500 and Dow Jones Industrial Average experiencing their fourth consecutive losses due to AI bubble concerns and tepid labor data, the t...
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
Provided Update on R&D Engine Now On Track to Deliver Multiple First- and Best-in-Class Medicines, Positioning Company for Long-Term Value Creation Across Therapeutic Modalities Reviewed Positive Dat...
Neurocrine Biosciences to Host R&D Day on December 16
SAN DIEGO, Dec. 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will hold its 2025 R&D Day on Tuesday, December 16, 2025, at 12:00 p.m. Eastern Time (9:00 a...
Leading Drug Stock Fights To Regain Buy Point At Key Resistance Level
Neurocrine Biosciences stock, part of the high-ranking biotech industry group, is trading back inside a buy zone. Continue Reading
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
